Literature DB >> 23795157

Ontario pharmacists concerned about the risks arising from approval of generic OxyContin.

Kathie Lynas.   

Abstract

Entities:  

Year:  2013        PMID： 23795157      PMCID： PMC3676250          DOI： 10.1177/1715163512473928

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  5 in total

1.  A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health Data.

Authors:  Kristen A Morin; Matthiew D Parrotta; Joseph K Eibl; David C Marsh
Journal:  Eur Addict Res       Date:  2021-03-11       Impact factor: 3.015

Review 2.  The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight.

Authors:  Joseph K Eibl; Kristen Morin; Esa Leinonen; David C Marsh
Journal:  Can J Psychiatry       Date:  2017-05-19       Impact factor: 4.356

3.  Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.

Authors:  Joseph K Eibl; Tara Gomes; Diana Martins; Ximena Camacho; David N Juurlink; Muhammad M Mamdani; Irfan A Dhalla; David C Marsh
Journal:  J Addict Med       Date:  2015 Nov-Dec       Impact factor: 3.702

4.  Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'.

Authors:  Joseph K Eibl; Kristen A Morin-Taus; David C Marsh
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-09-20

5.  The opioid crisis: past, present and future policy climate in Ontario, Canada.

Authors:  Kristen A Morin; Joseph K Eibl; Alexandra M Franklyn; David C Marsh
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.